Taysha Gene Therapies
Taysha Gene Therapies Inc is an American clinical-stage biopharmaceutical company focused on developing AAV-based gene therapies for monogenic central nervous system disorders. The company's primary focus is TSHA-102, an adeno-associated virus vector gene therapy in clinical development for the treatment of Rett syndrome. Principal revenue is currently driven through development milestone payments, strategic partnerships, and capital raises ahead of commercial authorization. Core end markets encompass pediatric neurology centers, rare disease clinical institutes, and specialized healthcare providers globally. Taysha Gene Therapies holds an innovative position in the biopharmaceutical sector as a developer of targeted adeno-associated virus gene therapies for severe neurodevelopmental conditions. The company is headquartered in Dallas, Texas, and its common stock trades on the Nasdaq Global Select Market.
3 of the funds FundTelligence covers report a position in Taysha Gene Therapies.
- Legal name
- TAYSHA GENE THERAPIES
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Taysha Gene Therapies
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.09 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)